If a clinician is contemplating iDeglira or iGlarlixi in a T2D patient on an oral antidiabetic agent who is not meeting HA1c goals, should the oral medication be adjusted in any way, or discontinued?

If a clinician is contemplating iDeglira or iGlarlixi in a T2D patient on an oral antidiabetic agent who is not meeting HA1c goals, should the oral medication be adjusted in any way, or discontinued?

If a clinician is contemplating the use of iDeglira or iGlarlixi in a T2D patient already on an oral antidiabetic agent who is not meeting HA1c goals, should the oral medication be adjusted in any way, or should it be discontinued?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Chantal Mathieu, MD, PhD

Chantal Mathieu, MD, PhD

Professor of Medicine
Program Director of Biomedical Sciences
Katholieke Universiteit
Chair of Endocrinology
University Hospital Gasthuisberg
Leuven, Belgium